GYRE (Gyre Therapeutics) Other Current Payables: $0.2 Mil (As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
43 GF Score
Price $7.00
GF Value $9.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Other Current Payables?

Gyre Therapeutics GYRE -3.44% 43 Other Current Payables is $0.2 Mil as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 43/100 and a GF Value™ of $9.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Gyre Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.2 Mil.

Gyre Therapeutics's quarterly Other Current Payables declined from Sep. 2025 ($3.9 Mil) to Dec. 2025 ($2.7 Mil) and declined from Dec. 2025 ($2.7 Mil) to Mar. 2026 ($0.2 Mil).

Gyre Therapeutics's annual Other Current Payables declined from Dec. 2023 ($4.6 Mil) to Dec. 2024 ($2.3 Mil) but then increased from Dec. 2024 ($2.3 Mil) to Dec. 2025 ($2.7 Mil).

Gyre Therapeutics Other Current Payables Related Terms

Gyre Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Other Current Payables Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
7.15 2.61 4.61 2.35 2.66

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.03 5.31 3.93 2.66 0.23
GYRE
43GF Score
Gyre Therapeutics Inc GYRE
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.2 Mil mean?
Gyre Therapeutics (GYRE) has a Other Current Payables of $0.2 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Other Current Payables too high?
Gyre Therapeutics' current Other Current Payables is $0.2 Mil. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Other Current Payables compare to RLMD and ACRS?
Gyre Therapeutics' Other Current Payables of $0.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Other Current Payables is $0.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $7.00 — trading 28.7% below its estimated fair value. The current Other Current Payables is $0.2 Mil. Gyre Therapeutics' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Other Current Payables is $0.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $7.00 is trading 28.7% below its estimated GF Value™ of $9.81. GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.

Key valuation signals for GYRE:

  • Other Current Payables: $0.2 Mil
  • GF Value™: $9.81 vs. price of $7.00 (28.7% below fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score

Get the complete analysis for GYRE

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$9.81
GF Value